#FDA Approval #Norway #Oslo #neurosurgery #SonoClear

SonoClear® System Moves Forward in FDA Review Process

In a significant stride for surgical technology, SonoClear AS, based in Oslo, Norway, has recently confirmed that its 510(k) submission for the innovative SonoClear® System has been accepted for thorough review by the U.S. Food and Drug Administration (FDA). This development is critical as it brings the company one step closer to obtaining approval to market their pioneering intraoperative ultrasound product in the United States. Notably, the SonoClear System has previously been granted Breakthrough Device Designation, emphasizing its potential impact in the field of neurosurgery.

SonoClear's CEO, Peter Balmforth, expressed enthusiasm regarding this milestone, stating, "Acceptance of this submission brings us an important step closer to our goal of making the SonoClear System available to U.S. neurosurgeons." The technology is designed specifically to enhance the visualization of surgical cavities during operations for brain tumors, thereby improving the decision-making process for surgeons engaged in these intricate procedures. The system aims to deliver clearer imaging by mitigating acoustic artifacts typically encountered with standard irrigation methods.

The effectiveness of the SonoClear System was evidenced in a pivotal 44-patient study, which was presented at the 2026 annual congress of the European Association of Neurosurgical Societies (EANS) by Professor Francesco DiMeco of the University of Milan. In this study, SonoClear achieved both its primary and secondary safety goals, significantly enhancing image quality compared with traditional techniques. This data sparked considerable excitement among the audience at the congress, indicating a strong interest in the system's commercial potential as feedback was collected from prospective users.

The Technology Behind the SonoClear System

The SonoClear System is a novel acoustic coupling fluid that has been clinically engineered to be sterile, biocompatible, and bioexcretable, making it suitable for use in brain tumor resections. By matching the acoustic properties of brain tissue, it reduces the visual distortions and noise that typically interfere with decision-making during surgery.

The potential benefits for surgeons using the SonoClear System are significant. By providing a more accurate and clearer view of the surgical field, the system may not only enhance diagnostic accuracy but also improve the extent of tumor resection while decreasing the chances of residual disease. As it stands, the technology is still considered investigational and has not yet been authorized for sale or distribution in the market.

About SonoClear AS

SonoClear AS emerged from the Ultrasound and Image-Guided Therapy Centre located in Trondheim, Norway. The organization is committed to advancing technology that enhances diagnostic accuracy in ultrasound-guided surgical interventions. The company is supported by several prominent shareholders, including SINTEF Venture IV, Sarsia, CoFounder, and Sparebank 1 SMN, as well as various private investors and family offices.

With the ongoing review process by the FDA, SonoClear AS has set its sights on future commercialization of the SonoClear System, promising a transformative impact on neurosurgical practices. As the medical community anticipates the potential approval and market introduction, the patient outcomes and operational efficiencies that could arise from using this advanced imaging technology remain an exciting prospect for neurosurgeons and their patients alike.